Phost’in Therapeutics

Phost’in Therapeutics is a clinical-stage French biotechnology company specializing in the development of first-in-class small molecule inhibitors targeting aberrant glycosylation in cancer. The company's lead program, PhOx430, is a selective inhibitor of the GnT-V (N-acetylglucosaminyltransferase V) enzyme, which is overexpressed in many aggressive solid tumors and contributes to immune evasion and metastasis. By targeting this specific glyco-enzyme, Phost’in aims to restore the body's natural immune response against cancer cells. The company is currently evaluating PhOx430 in Phase 1/2 clinical trials for patients with advanced solid tumors, including glioblastoma. Founded as a spin-off from academic research, Phost’in leverages a proprietary platform to address high unmet needs in oncology.